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ABSTRACT
Objective To report the 10-year follow-up of the
MAINTAIN Nephritis Trial comparing azathioprine (AZA)
and mycophenolate mofetil (MMF) as maintenance
therapy of proliferative lupus nephritis, and to test
different deﬁnitions of early response as predictors of
long-term renal outcome.
Methods In 2014, data on survival, kidney function,
24 h proteinuria, renal ﬂares and other outcomes were
collected for the 105 patients randomised between 2002
and 2006, except in 13 lost to follow-up.
Results Death (2 and 3 in the AZA and MMF groups,
respectively) and end-stage renal disease (1 and 3,
respectively) were rare events. Time to renal ﬂare (22
and 19 ﬂares in AZA and MMF groups, respectively) did
not differ between AZA and MMF patients. Patients with
good long-term renal outcome had a much more
stringent early decrease of 24 h proteinuria compared
with patients with poor outcome. The positive predictive
value of a 24 h proteinuria <0.5 g/day at 3 months, 6
months and 12 months for a good long-term renal
outcome was excellent (between 89% and 92%).
Inclusion of renal function and urinalysis in the early
response criteria did not impact the value of early
proteinuria decrease as long-term prognostic marker.
Conclusions The long-term follow-up data of the
MAINTAIN Nephritis Trial do not indicate that MMF is
superior to AZA as maintenance therapy in a Caucasian
population suffering from proliferative lupus nephritis.
Moreover, we conﬁrm the excellent positive predictive
value of an early proteinuria decrease for long-term renal
outcome.
Trial registration number NCT00204022.
INTRODUCTION
Maintenance immunosuppressive therapy of lupus
nephritis (LN) is justiﬁed by the relapsing nature of
the disease,1 especially as recurrent episodes of
glomerulonephritis negatively impact long-term
renal outcome. The goal of chronic immunosup-
pression in LN is to control the underlying immune
processes without unacceptable drug toxicity. In
this respect, it must be stressed that side effects of
glucocorticoids (GCs) account for most of the
damage accrual in patients with systemic lupus ery-
thematosus (SLE),2 3 thereby fully justifying the use
of other immunosuppressants as steroid-sparing
agents.
Mycophenolate mofetil (MMF) and azathioprine
(AZA) are the most commonly prescribed drugs for
maintenance therapy. They have been compared in
two recent controlled randomised trials. Thus, in the
Aspreva Lupus Management Study (ALMS), MMF
was found superior to AZA to prevent treatment fail-
ures and renal ﬂares at 3 years in patients with LN
who had responded to 6-month induction therapy by
intravenous cyclophosphamide (CY) or MMF.4 By
contrast, after a mean follow-up of 4 years, MMF
was not found superior to AZA in the MAINTAIN
Nephritis Trial,5 in which the two drugs were com-
pared after a short course of low-dose intravenous
CY, that is, the Euro-Lupus regimen.6 The ﬁrst object-
ive of this analysis is to report on the 10-year
follow-up of the trial, including the per protocol
period (5 years) and the long-term outcome. The
second objective is to identify early prognostic factors
capable of predicting poor long-term renal outcome.
Since chronic renal impairment and a fortiori end-
stage renal disease (ESRD) are relatively rare and
usually late events in the disease course, only long-
term reports can address this pivotal question.
Here we show that: (1) long-term follow-up of
the MAINTAIN cohort fails to unmask an advan-
tage of MMF over AZA as maintenance therapy of
LN; (2) an early decrease in proteinuria has a high
positive predictive value for good long-term renal
outcome; and (3) proteinuria decrease is sufﬁcient
to deﬁne early complete response (CR) as a surro-
gate for good long-term renal outcome.
PATIENTS AND METHODS
Patient selection
Between July 2002 and March 2006, 105 European
patients fulﬁlling the classiﬁcation criteria for SLE,7
aged ≥14 years, suffering from biopsy-proven prolif-
erative WHO Class III, IV, Vc or Vd glomeruloneph-
ritis and displaying ≥500 mg/24 h proteinuria were
randomised in the MAINTAIN Nephritis Trial, after
having signed informed consent. This investigator-
initiated study was conducted according to the Good
Clinical Practice guidelines of the European Medicines
Agency, did not receive external funding, and was
registered at ClinicalTrials.gov (NCT00204022).
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Treatment
All patients received three daily 750 mg intravenous methyl-
prednisolone pulses (days 1–3), followed by oral GC therapy
started on day 4 at an initial dose of 0.5 mg equivalent prednis-
olone/kg/day for 4 weeks. From week 4 onwards, GCs were
tapered by 2.5 mg prednisolone/day every 2 weeks, down to
7.5 mg/day at week 24 and to 5 mg/day at week 52. From week
76 onwards, it was advised to taper the steroids further and to
stop them if possible. All patients received six fortnightly intra-
venous CY pulses of 500 mg (ﬁxed dose) within a 10-week
period and were then started, from week 12 onwards, on AZA
(target dose: 2 mg/kg/day) or MMF (target dose 2 g/day),
according to randomisation performed at baseline and irrespec-
tively of the magnitude of their renal response at 3 months.
AZA or MMF was prescribed per protocol for 5 years, unless
inefﬁcacy or intolerance occurred. After this period, the decision
to stop or to continue immunosuppressive treatment was left to
the patient’s and physician’s decision. ACE inhibitors were man-
datory in patients with nephrotic-range proteinuria (≥3 g/day)
and strongly recommended in others.
End points
The primary end point of the trial was time to renal ﬂare, ana-
lysed by Kaplan-Meier survival curves computed on the
intent-to-treat population. A renal ﬂare was deﬁned as (1) the
recurrence or the development of nephrotic syndrome or—only
for patients with low-grade baseline 24-h proteinuria (≥0.5 and
<1 g)—a threefold increase of 24 h proteinuria within a
3-month period (proteinuric ﬂare); or (2) renal impairment
(≥33% increase of serum creatinine within a 1-month period
directly attributed to lupus and conﬁrmed) (nephritic ﬂare).
After a mean period of 48 months, renal ﬂares were observed in
25% (n=13) and 19% (n=10) of AZA-treated and
MMF-treated patients, respectively.5 In January 2014, investiga-
tors were asked to provide long-term follow-up data on their
patients including cause of death, new renal ﬂares, renal func-
tion and proteinuria at last follow-up, current treatment, cumu-
lative use of immunosuppressants and biologics and severe
adverse events. Of note, these data were collected within the
frame of standard of care, as all patients had terminated the
5-year protocol between 3 years and 6.5 years before current
data reporting.
Statistical analyses
As described elsewhere,5 MAINTAIN was designed as a superior-
ity trial of MMF over AZA. The primary endpoint (time to
renal ﬂare) was used for power calculation. We anticipated a
renal ﬂare rate of 35% at 5 years in the AZA group. We deﬁned
the clinically meaningful difference as a 10% ﬂare rate in the
MMF group. To detect such a difference, 51 patients needed to
be randomised in each arm to obtain a power of 0.80 with an α
level of 0.05. Kaplan-Meier survival curves were statistically
tested with the logrank test. HRs and their 95% CIs were calcu-
lated using the univariate Cox proportional-hazards model.
Unpaired t tests, Mann-Whitney’s tests, χ2 tests or Fisher’s exact
tests were used as appropriate. All analyses were by
intent-to-treat, except the Kaplan-Meir curves.
RESULTS
Long-term follow-up of the MAINTAIN cohort fails to
unmask differences between AZA and MMF as maintenance
therapy of LN
Of 105 patients randomised in the MAINTAIN Nephritis Trial, 5
died and 13 were lost to follow-up. Median (range) duration of
follow-up was 110 (18–156) months. Of note, baseline character-
istics of patients lost to follow-up did not differ from those who
were not followed long-term (data not shown). Death was due to
sepsis in four patients (at month 36, month 47, month 92 and
month 119; two patients assigned to AZA and two to MMF) and
to SLE in one case (at month 45; MMF patient). As illustrated by
Figure 1 Kaplan–Meier analysis of the probability of an absence of end-stage renal disease (ESRD) (A), all types of renal ﬂare (B), proteinuric ﬂare
(C) and nephritic ﬂare (D). All patients received Euro-Lupus intravenous cyclophosphamide, followed by azathioprine (AZA) or mycophenolate mofetil
(MMF) as maintenance therapy. Survival curves were statistically tested with the logrank test. HR (95% CI). Numbers shown in abscissa are the
number of patients at risk in each group at each time point. Analysis was by intention-to-treat.
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the Kaplan Meier survival curves shown in ﬁgure 1A, time to
ESRD (one AZA and three MMF patients) did not differ
between groups. Mean (SD) serum creatinine at last follow-up
was 0.85 (0.4) mg/dL and 0.85 (0.7) mg/dL for AZA and MMF
patients, respectively (p>0.99). Percentages of patients with esti-
mated glomerular ﬁltration rate (eGFR) <60 mL/min/1.73 m2
(19% and 11% in AZA and MMF groups, respectively; p=0.39
by Fischer’s exact test), with serum creatinine >120% of baseline
value (23% and 23%, respectively; p>0.99) or with serum cre-
atinine >1 mg/dL (19% and 20%, respectively; p>0.99) at last
follow-up did not statistically differ. Median daily proteinuria
was 0.55 g at last follow-up in AZA patients and 0.70 g in MMF
patients (p=0.58). Time to renal ﬂare (all, proteinuric or neph-
ritic) did not differ between groups (ﬁgure 1B–D). At last
follow-up, 22 AZA patients had suffered from a renal ﬂare (pro-
teinuric in 18 and nephritic in 4), compared with 19 patients
assigned to MMF (proteinuric in 12, nephritic in 6 and undeter-
mined in 1). Table 1 compares the treatment of the two groups at
last visit, as well as the need for additional immunosuppressants
during follow-up. Of note, even 10 years after the diagnosis of
LN, more than half of the patients were still on low-dose GC
and/or another immunosuppressant. Interestingly, a third of the
patients assigned to AZA or MMF were still taking the same drug
at very long-term follow-up, at a mean (SD) daily dose of 95 (37)
mg and 1.8 (0.7) g, respectively. AZA/MMF switch had occurred
in 20% and 14% of AZA and MMF patients, respectively. The
need for additional immunosuppressive therapy was similar in
the two groups. These treatment changes were explained by
renal and non-renal ﬂares, as well as by pregnancy plans, which
imposed switches from MMF to AZA. Severe adverse events
(deﬁned by the need for inpatient treatment) were equally
common (42% and 36% of AZA and MMF patients during the
10 year follow-up, respectively). Of AZA and MMF patients
19% and 21%, respectively, had successful pregnancies during
follow-up. Cancer was diagnosed in three patients, two from the
AZA group (cervix) and one from the MMF arm (thyroid).
Baseline data do not predict long-term renal outcome
Next, we investigated whether long-term renal outcome could
be predicted by baseline data, obtained at randomisation in the
trial. A good long-term renal outcome group and a poor long-
term renal outcome group were deﬁned based on the patient’s
last creatinine, namely ≤120% of baseline value for good
responders (n=83) and >120% for poor responders (n=21). As
indicated in table 2, none of the baseline clinical, biological or
pathological parameters tested statistically differed between
these two groups. This remained true when other cut-offs of
renal impairment (cf supra) were used to deﬁne good or poor
renal outcome (data not shown).
Table 2 Baseline data of patients with good or poor long-term renal outcome*
Good outcome (n=83) Poor outcome (n=21) p Value†
ECLAM (median, range) 7 (2–10) 7 (4–10) 0.85
SLEDAI (median, range) 19 (4–38) 15 (9–24) 0.09
Systolic blood pressure (mm Hg) (mean±SD) 128±17 131±17 0.61
Diastolic blood pressure (mmHg) (mean±SD) 78±11 79±8 0.81
Serum creatinine (mg/dL) (mean±SD) 1.04±0.41 0.80±0.35 0.07
Proteinuria (g/d) (mean±SD) 3.1±2.5 3.4±2.9 0.71
Serum albumin (g/dL) (mean±SD) 3.0±0.7 2.8±0.7 0.11
Serum complement C3 (mg/dL) (mean±SD) 57±55 52±33 0.69
uRBCs ≥5/hpf (%) 87 82 0.70
WHO class III/IV/Vc/Vd (%) 29/60/4/7 43/52/0/5 0.55
*Long-term renal outcome was defined based on last serum creatinine (≤120% of baseline value for good responders and >120% for poor responders).
†By Mann-Whitney U-test for ECLAM and SLEDAI, Fisher’s exact test for RBCs, χ2 test for WHO class and unpaired t-test for the other values.
ECLAM, European Consensus Lupus Activity Measurement; hpf, high power field; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; uRBCs, urinary red blood cells.
Table 1 Treatment in the MAINTAIN Nephritis Trial Cohort at 10 years of follow-up*
All (n=87) MMF group (n=42) AZA group (n=45) p Value†
Follow-up (months; median/range) 110/18–156 105/18–156 114/18–152 0.80
Age at follow-up (years; median/range) 42±10 42±9 42±10 0.84
Currently on GC (%) 56 57 55 0.83
Mean prednisolone daily dose (mg)‡ 7.0±6.2 6.6±4.5 7.3±7.6 0.68
Currently on IS (%) 56 55 58 0.83
Currently on AZA (%) 24 14 33 0.047
Currently on MMF (%) 27 36 20 0.15
Currently on BPLD (%) 65 74 58 0.18
Need for additional IS therapy (%) 41 36 47 0.38
Need for additional intravenous CY (>3 g) (%) 19 14 20§ 0.57
Need for RTX (%) 11 12 11 >0.99
*Data on patients alive and not lost to follow-up.
†By unpaired t test or Fisher’s exact test.
‡Calculated for patients on GC only.
§One AZA patient received additional intravenous CY for a neuropsychiatric non-renal flare.
AZA, azathioprine; BPLD, blood pressure lowering drug; GC, glucocorticoid; IS, immunosuppressant; CY, cyclophosphamide; MMF, mycophenolate mofetil; RTX, rituximab.
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An early decrease in proteinuria has a high positive
predictive value for good long-term renal outcome
We then analysed whether the kinetics of proteinuria decrease
within the 1st year of treatment differed between patients with
good or poor late renal outcome, as previously deﬁned. As
shown in ﬁgure 2, proteinuria decreased much more promptly
and dramatically in patients with a good long-term renal
outcome. Of note, this remained true when different deﬁnitions
of good/poor long-term outcome were applied (last eGFR ≥ or
<60 mL/min/1.73 m2 of body surface area, last serum creatinine
≤ or >1 mg/dL or last serum creatinine < or ≥1.4 mg/dL) (see
online supplementary ﬁle 1). The positive predictive value of an
early proteinuria decrease ≤0.5 g/d for a good long-term
outcome (in casu last serum creatinine value ≤120% of baseline)
was excellent, that is, 89% at 3 months (24 patients with good
late outcome among 27 who achieved such a level of protein-
uria reduction), 90% at 6 months (38/42) and 92% (47/51) at
12 months. By contrast the negative predictive value of a pro-
teinuria level >0.5 g/d was low (21%, 29% and 32% at 3
months, 6 months and 12 months, respectively), since many
patients without a strictly deﬁned proteinuria decrease also
achieved good 10-year renal outcomes.
Proteinuria decrease is sufﬁcient to deﬁne early CR as a
surrogate for good long-term renal outcome
Finally, we investigated whether inclusion of renal function and
urinalysis in the early response criteria improved the value of a
deﬁned proteinuria decrease as a long-term prognostic marker.
As explained in table 3, we deﬁned early CR, partial response
(PR) and no response (NR) using three different sets of criteria,
based on assessment of (1) proteinuria alone; (2) proteinuria
and serum creatinine; and (3) proteinuria, serum creatinine and
the presence of red blood cells in the urinalysis. CR, PR and
NR were evaluated at 3 months, 6 months and 12 months.
Table 4 shows the percentages of good long-term renal respon-
ders in patients achieving CR, PR and NR, at different time
sets. The data demonstrate that proteinuria decrease alone
drives the positive predictive value of the response at
12 months. Thus, the positive predictive value of a 12-month
CR for a good 10-year outcome was 92%, 94% and 93%, using
the three aforementioned criteria sets, respectively. At 3 months
and 6 months, the addition of urinalysis slightly improved the
positive predictive value of a CR but very few patients achieved
such a strict deﬁnition.
DISCUSSION
Current standard treatment of LN consists of two phases: an
initial phase to induce a sufﬁcient level of response—and ideally
complete renal remission—and a subsequent phase to maintain
the response, keeping in mind that the primary objective is the
prevention of any level of renal impairment in the very long
term with minimal drug-related toxicity.8 Optimal induction
treatment is more easy to deﬁne than maintenance therapy
because short-term (6–12 months) trials provide appropriate
answers for the former, while long-term studies (at least 3 years)
must be designed for the latter. Thus, induction trials—and the
corresponding meta-analyses—have convincingly demonstrated
that intravenous CY and MMF are equally efﬁcacious and toxic
at 6 months,9–11 even when severely affected patients with some
degree of renal impairment are included at baseline.12 This con-
clusion should not overlook pivotal issues related to induction
therapy which remain unsolved, such as the dose of—or even
the need for—GCs13 and the place of targeted therapy.14
Until 15 years ago, quarterly pulses of intravenous CY were
used as maintenance therapy of LN, based on studies performed
by the National Institutes of Health group.15 In a seminal paper
published in 2004, Contreras et al16 demonstrated that patients’
survival was better and chronic renal impairment less frequent
when AZA or MMF was used as maintenance therapy instead
of quarterly pulses of intravenous CY, thereby contributing to a
reduction in the use of the latter regimen as maintenance treat-
ment, especially as its use was associated with unacceptable
gonadal toxicity and increased mortality. Two randomised trials
have speciﬁcally compared MMF and AZA as maintenance
therapy. While the largest—the ALMS—showed superiority of
MMF over AZA for the prevention of renal relapses,4 this is not
the case in the MAINTAIN Nephritis Trial, neither in the ﬁrst
report,5 nor in this long-term analysis, as demonstrated here.
The discrepancy between MAINTAIN and ALMS may have
Figure 2 Differential kinetics of 24 h proteinuria decrease in patients
with a good and poor long-term renal outcome. Data are shown at
baseline and after 3 months, 6 months and 12 months of treatment for
patients with good long-term renal outcome (serum creatinine ≤120%
of baseline value; n=83) or poor long-term renal outcome (serum
creatinine >120% of baseline value; n=21). p Values indicated above
the columns were calculated by Mann-Whitney tests.
Table 3 Definitions of CR, PR and NR using different criteria sets
Criteria set CR PR NR
Proteinuria Proteinuria ≤0.5 g/d Proteinuria >0.5 g/d but ≥50% decrease Proteinuria >0.5 g/d but <50% decrease
Proteinuria+sCr Proteinuria ≤0.5 g/d Proteinuria >0.5 g/d but ≥50% decrease Proteinuria >0.5 g/d but <50% decrease
sCr ≤120% baseline sCr ≤120% baseline sCr >120% baseline
Proteinuria+sCr+uRBC Proteinuria ≤0.5 g/d Proteinuria >0.5 g/d but ≥50% decrease Proteinuria >0.5 g/d but <50% decrease
sCr ≤120% baseline sCr ≤120% baseline sCr >120% baseline
uRBC ≤5/hpf uRBC >5/hpf uRBC >5/hpf
CR, complete response; hpf, high power field; NR, no response; PR, partial response; sCr, serum creatinine; uRBCs, urinary red blood cells.
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several explanations. Thus, the design of the two trials is differ-
ent: in ALMS, patients received two different induction regimes
and were randomised in the maintenance phase only if they had
achieved a signiﬁcant level of response at 6 months, while in
MAINTAIN all patients received the same induction treatment,
namely Euro-Lupus intravenous CY, and were switched to AZA
or MMF at 3 months, irrespective of their response to induction
therapy. Moreover, the ethnic background considerably differs
between the two trials, with a much greater proportion of
non-Caucasians in ALMS compared with MAINTAIN (56% vs
17%). In the long-term follow-up discussed here, we looked for
renal relapses and for hard outcomes such as ESRD and any
degree of chronic renal impairment, which can be addressed
only by long-term assessments, as these events are relatively
rare. At 10 years, renal failure rates were similar in the two
arms, well in line with the pathological data obtained by a
2-year repeat renal biopsy study performed in an unselected
subset of MAINTAIN patients, which failed to show differences
in chronicity indices between MMF and AZA patients.17 Taken
together, the long-term follow-up of MAINTAIN corroborates
the results of three recent meta-analyses (which included only
the 5-year MAINTAIN report) concluding that superiority of
MMF over AZA as maintenance therapy of LN cannot be
demonstrated, certainly not for hard outcomes such as death or
chronic renal failure.18–20
The MAINTAIN data clearly conﬁrms that an early decrease in
proteinuria levels within the 1st year of treatment is highly predict-
ive for a good long-term renal outcome, as previously demon-
strated in the Euro-Lupus Nephritis Trial.21 22 Of note, baseline
data did not differ between good and poor long-term renal
responders, very much in contrast to initial response to therapy. In
this report, we show that patients whose proteinuria is ≤0.5 g/d at
12 months (half of the entire cohort) run a very low risk (8%) of
any level of long-term renal impairment at 10 years. By contrast,
the negative predictive value is low, which means that most
patients without such a strictly deﬁned early decrease in protein-
uria will still have a good renal outcome at 10 years. The negative
predictive value is not at all improved by the addition of serum
creatinine data and results of urinalysis in the criteria set used to
deﬁne early response. At the bedside, the clinician can therefore
conﬁdently reassure patients who achieve a durable early response
in proteinuria but should not consider a switch to an alternative
agent based only on non-achievement of this target.
It is current practice to include the results of urinalysis in the
deﬁnition of complete renal response, as proposed by American
College of Rheumatology (ACR) recommendations for response
criteria in LN clinical trials23 and by European League Against
Rheumatism (EULAR) recommendations for monitoring patients
with SLE in clinical practice and observational studies.24 These
recommendations were applied in studies aimed at testing the
efﬁcacy of rituximab (LUNAR; Lupus Nephritis Assessment with
Rituximab study)25 or abatacept in LN.26 Yet, the persistence of
microhaematuria within the 1st year of LN treatment is no
longer considered by nephrologists as a predictive biomarker of
poor long-term renal outcome.27 Therefore, some newer LN
trials, such as ACCESS (Abatacept and Cyclophosphamide
Combination Efﬁcacy and Safety Study), do not include urinalysis
in the deﬁnition of the primary outcome (clinicaltrials.gov identi-
ﬁer NCT00774852). The MAINTAIN data presented here are
consistent with this decision, as they indicate that proteinuria
alone drives the positive predictive value of the response at
12 months. Persistent haematuria at 12 months should therefore
not inﬂuence treatment decisions at the bedside. To examine this
issue further, investigators from the Lupus Nephritis Trials
Network are currently analysing the Euro-Lupus Nephritis Trial
data again, for which long-term follow-up is also available,22
with the idea to test short-term predictors of long-term outcome.
The MAINTAIN Nephritis Trial suffers from limitations,
which have already been discussed at length in the manuscript
dealing with the 5-year per protocol data,5 in particular the rela-
tively small number of patients included in the trial. Needless to
say, as further treatment was left to patient’s choice and physi-
cian’s judgement, numerous treatment changes occurred
between year 5 and year 10, for many different reasons, includ-
ing non-renal issues, thereby complicating interpretation of
long-term data. Yet, hard outcomes, such as death, ESRD and
last creatinine, which can be addressed only by long-term
studies, did not differ whatsoever between the AZA and MMF
groups at long-term follow-up. Despite these limitations, the
data presented here thereby conﬁrm the relevance of EULAR/
ERA-EDTA (European Renal Association-European Dialysis and
Transplant Association)28 and ACR recommendations29 regard-
ing maintenance therapy of LN, namely that AZA and MMF
can be prescribed. Moreover, our data provide compelling evi-
dence that an early proteinuria decrease is an excellent predictor
of good long-term outcome, again an observation that can be
obtained only by investigator-initiated long-term trials.
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